An Ohio lake, a boatload of floating granules, and a treatment reported at under $30,000. BlueGreen’s wager is that where you put the chemistry matters as much as what you put in.
Lumen survived a biofuel bust and a pigment-price collapse by turning stubborn green microbes into miniature drug factories. Now its oral biologics face the test that matters: whether an elegant manufacturing trick can survive large clinical trials and the economics of medicine.